PROCESS FOR PRODUCING PROVITAMIN D COMPOUNDS

Abstract: A process for producing a compound represented by general formula (II) by the reaction of an epoxy compound represented by general formula (I) with an alcohol under a basic condition, wherein R₁ represents hydrogen or a protective group; R₂ represents hydrogen or hydroxy; R₃, R₄, R₅ and R₆ represent such groups that a pair of R₃ and R₄ and a pair of R₅ and R₆ form each a double bond, or a pair of R₄ and R₅ forms a double bond while R₃ and R₆ are bonded to a dienophile capable of protecting conjugated double bonds; and R₇ represents lower alkyl, cycloalkyl or optionally protected lower hydroxyalkyl. This process is one for synthesizing an intermediate of a vitamin D derivative in an imptroved yield without the necessity for complicated procedure of protection and is also suited for mass production.

Description: The present invention relates to a process for synthesizing provitamin D compounds or provitamin D compounds in which the 5,7-diene structure is protected which are intermediates for synthesis of vitamin D derivatives having a substituent at the 2β-position which have various physiological activities such as a calcium controlling activity in vivo and a differentiation deriving activity of tumor cells, etc. More specifically, the present invention relates to a process for introducing a substituent into the 2β-position by reacting a 1α,2α-epoxy compound with an alcohol under a basic condition. Background Art Hitherto, in introducing a substituted lower alkoxy group at the 2β-position of vitamin D derivatives, a process in which the addition reaction of an alcohol to 1α,2α-epoxy compound is carried out under an acidic condition has been known (Japanese Patent Application (Kokai) No. 61-267549), but this process is not satisfactory due to its low yield, etc. Disclosure of Invention As a result of extensive studies, the present inventors found that, in introducing a substituent at the 2β-position by reacting a 1α,2α-epoxy compound (1) represented by the formula (I): (wherein R 1 represents a hydrogen atom or a protective group, R 2 represents a hydrogen atom or a hydroxyl group, R 3 , R 4 , R 5 and R 6 represent that each of R 3 and R 4 , and R 5 and R 6 forms a double bond, or R 4 and R 5 form a double bond, and R 3 and R 6 bond to dienophile which is capable of protecting a conjugated double bond), with an alcohol, the reaction proceeds even under a basic condition whereby a ring-cleaved product represented by the following formula (II) can be obtained in a high yield: (wherein R 1 represents a hydrogen atom or a protective group, R 2 represents a hydrogen atom or a hydroxyl group, R 3 , R 4 , R 5 and R 6 represent that each of R 3 and R 4 , and R 5 and R 6 forms a double bond, or R 4 and R 5 form a double bond, and R 3 and R 6 bond to dienophile which is capable of protecting a conjugated double bond, and R 7 represents a lower alkyl group, a cycloalkyl group or a lower hydroxyalkyl group wherein the hydroxyl group may be protected.) In the above reaction, protection of some functional groups which has been considered necessary in a conventional ring-cleaving reaction under an acidic condition becomes to be unnecessary, but the reaction may be carried out while protected. Further, in the process of this invention, the ring-cleaved product can be obtained in a high yield as compared with the reaction under an acidic condition. The provitamin D 3 derivatives prepared according to the process of this invention can be converted into the corresponding vitamin D 3 derivatives by subjecting the provitamin D 3 derivatives to the conventional thermal isomerization after irradiation with U.V. light. In the present invention, examples of the protective groups in the formula include an acyl group such as an acetyl group, a pivaloyl group, a methoxycarbonyl group, a benzyloxycarbonyl group and a p-toluenesulfonyl group, an alkyl group which may be substituted such as a methyl group and a methoxymethyl group, and a substituted silyl group such as a trimethylsilyl group, a triethylsilyl group and a t-butyldimethylsilyl group, and, preferably, a trimethylsilyl group, a triethylsilyl group and a t-butyldimethylsilyl group. The alcohol compound means an aliphatic monohydric or polyhydric alcohol having from 1 to 7 carbon atoms, and some of the hydroxyl groups thereof other than any one hydroxyl group thereof may be protected. Examples of the alcohol compound include propanol, butanol, pentanol, hexanol, cyclopropanol, cyclobutanol, cyclopentanol, cyclohexanol, ethylene glycol, 1,3-propanediol, 1,4-butanediol, 1,5-pentanediol, etc. The lower alkyl group means a straight chain or a branched alkyl group having from 1 to 6 carbon atoms, for example, a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an s-butyl group, a t-butyl group, etc. The cycloalkyl group means a cycloalkyl group having from 3 to 8 carbon atoms, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, etc. The lower hydroxyalkyl group means an alkyl group having from 1 to 7 carbon atoms wherein at least one hydrogen atom is substituted with a hydroxyl group, for example, a 2-hydroxyethyl group, a 3-hydroxypropyl group, a 4-hydroxybutyl group, etc., preferably a 3-hydroxypropyl group. The ring cleaving reaction according to the present invention can be carried out with or without using a solvent, and, when the solvent is used, examples thereof include ether type solvents such as tetrahydrofuran and dioxane, and aromatic type solvents such as benzene and toluene. Preferably, the reaction is carried out with benzene or without any solvent. The reaction temperature can be from 50 to 150°C preferably from 80 to 120°C. The compound represented by the formula (I): (wherein R 1 represents a hydrogen atom or a protective group, R 2 represents a hydrogen atom or a hydroxyl group, R 3 , R 4 , R 5 and R 6 represent that each of R 3 and R 4 , and R 5 and R 6 forms a double bond, or R 4 and R 5 form a double bond, and R 3 and R 6 bond to dienophile which is capable of protecting a conjugated double bond) which can be used in the present invention, can be synthesized by the process described in, for example, Japanese Patent Application (Kokai) Nos. 50-84555 and 50-84560, and J. Org. Chem., 57, 5019-5020(1992). The dienophile which is capable of protecting a conjugated double bond used in the present invention includes a compound represented by the formula (III): (wherein A and B, which may be the same or different, each represents an alkoxy group having from 1 to 4 carbon atoms, or A and B, when taken together, represent a phenylimino group or an o-phenylene group, and Y represents a nitrogen atom or a methine (=CH-) group), and preferably, 4-phenyl-1,2,4-triazoline-3,5-dione, diethyl maleate, etc. The basic condition means that a base is present in the reaction system. The base which can be used in the present invention includes a metal base such as a metal alkoxide, a metal hydride and the like, for example, potassium t-butoxide and sodium hydride, preferably potassium t-butoxide. The base may be used alone or in combination with an additive such as a Crown ether, and examples of the combination with the additive include sodium hydride + 15-Crown-5, potassium t-butoxide + 18-Crown-6, potassium t-butoxide + dibenzo 18-Crown-6 and the like, and preferably, potassium t-butoxide + dibenzo 18-Crown-6. The present invention is further illustrated by the following Examples and Reference Example in more detail. Reference Example 1 Synthesis of 3β,25-dihydroxy-1α,2α-epoxy-5,7-cholestadiene A solution of 49 mg (8.3 × 10 -5 mol) of 1α,2α-epoxy-5α,8α-(3,5-dioxo-4-phenyl-1,2,4-triazolidino)-6-cholestene-3β,25-diol) in DMI (5 ml) was stirred in an argon atmosphere at 140°C (bath temperature) for 5 hours. The reaction mixture was poured into water, and the resulting mixture was extracted twice with ethyl acetate, and then washed once with water. After drying the ethyl acetate layer over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by fractional thin layer chromatography (silica gel:ethyl acetate:n-hexane = 55:45) to obtain 21 mg (62% yield) of the titled compound as a white powder. Melting point : 173 - 175°C 1 H-NMR (CDCl 3 )δ : 0.64(3H,s), 0.97(3H,d,J=6.3Hz), 1.05(3H,s), 1.22(6H,s), 3.04(1H,d,J=3.4Hz), 3.33(1H,d,J=3.4Hz), 3.90(1H,dd,J=10.7,6.1Hz), 5.36-5.42(1H,m), 5.70-5.72(1H,m) MS(m/z) : 414(M + ), 59(100%) UV λmax(nm) : 290, 278, 268 Example 1 Synthesis of 2β-(3-hydroxypropoxy)-1a,3β,25-trihydroxycholesta-5,7-diene A mixture of 21 mg (5.1 × 10 -5 mol) of 3β,25-dihydroxy-1α,2α-epoxy-5,7-cholestadiene, 294 µℓ (4.1 × 10 -3 mol) of 1,3-propanediol, 19 mg (1.5 × 10 -4 mol) of potassium t-butoxide and 4.8 mg (1.3 × 10 -5 mol) of dibenzo-18-Crown-6 was stirred in an argon atmosphere at 110°C (bath temperature) for 4 hours. The reaction mixture was poured into water, and the resulting mixture was extracted twice with ethyl acetate and washed once with a saturated aqueous sodium chloride solution. After drying the ethyl acetate layer over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by fractional thin layer chromatography (silica gel:dichloromethane:ethanol = 100:15) to obtain 18 mg (72% yield) of the titled compound as a white powder. Melting point : 118 - 120°C 1 H-NMR(CDCl 3 )δ : 0.62(3H,s), 0.96(3H,d,J=6.3Hz), 1.06(3H,s), 1.22(6H,s), 5.32-5.42(1H,m), 5.64-5.73(1H,m) MS(m/z) : 490(M + ), 131(100%) UV λmax(nm) : 293, 281.5, 271, 262(shoulder) Example 2 Synthesis of 2β-(3-hydroxypropoxy)-1α,3β-dihydroxy-5,7-cholestadiene A mixture of 275 mg (6.9 × 10 -4 mol) of 1α,2α-epoxy-3β-hydroxy-5,7-cholestadiene, 4 ml (5.5 × 10 -2 mol) of 1,3-propanediol, and 258 mg (2.1 × 10 -3 mol) of potassium t-butoxide was stirred in an argon atmosphere at 110°C (bath temperature) for 4.5 hours. The reaction mixture was poured into water, and the resulting mixture was extracted twice with diethyl ether and washed three times with water. Sodium chloride was added to the aqueous layer, and the mixture was extracted twice with ethyl acetate and washed once with a saturated aqueous sodium chloride solution. After drying the combined organic layer over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by flash column chromatography (silica gel:dichloromethane:ethanol = 10:1) to obtain 229 mg (70% yield) of the titled compound as a white powder. Melting point : 114 - 116°C 1 H-NMR(CDCl 3 )δ : 0.62(3H,s), 0.87(6H,d,J=6.3Hz), 0.94(3H,d,J=6.8Hz), 5.32-5.39(1H,m), 5.63-5.73(1H,m) MS(m/z) : 474(M + ), 380(100%) UV λmax(nm) : 293, 282, 271, 262(shoulder) Examples 3 to 8 The following compounds were synthesized in the same manner as described in Example 2 except for using various alcohols in place of 1,3-propanediol. Example 3 2β-Butoxy-1α,3β-dihydroxycholesta-5,7-diene 1 H-NMR(CDCl 3 )δ : 0.63(3H,s), 0.87(6H,d,J=6.6Hz), 0.94(3H,d,J=6.9Hz), 1.07(3H,s), 3.41-3.50(1H,m), 3.66-3.74(2H,m), 3.83-3.99(2H,m), 5.34-5.42(1H,m), 5.68-5.74(1H,m) MS(m/z) : 472(M + ), 57(100%) UV λmax(nm) : 293, 281, 270 IR(cm -1 ) : 3450, 2980, 2900, 1480, 1400, 1110, 1060, 750 Example 4 2β-Cyclohexyloxy-1α,3β-dihydroxycholesta-5,7-diene 1 H-NMR(CDCl 3 )δ : 0.63(3H,s), 0.87(6H,d,J=6.6Hz), 3.39-3.96(4H,m), 5.31-5.41(1H,m), 5.56-5.63(1H,m) MS(m/z) : 498(M + ), 55(100%) UV λmax(nm) : 290, 279, 269 IR(cm -1 ) : 3450, 2950, 2900, 1090, Example 5 2β-Cyclohexyloxy-1α,3β,25-trihydroxycholesta-5,7-diene 1 H-NMR(CDCl 3 )δ : 0.63(3H,s), 0.96(3H,d,J=6.3Hz), 1.09(3H,s), 1.22(6H,s), 3.38-3.50(1H,m), 3.73-3.83(2H,m), 3.87-3.93(1H,m), 5.32-5.40(1H,m), 5.67-5.73(1H,m) MS(m/z) : 514(M + ), 55(100%) UV λmax(nm) : 293, 281, 271 IR(cm -1 ) : 3400, 2940, 2850, 1450, 1380, 990, 760 Example 6 2β-(4-Hydroxybutoxy)-1α,3β,25-trihydroxycholesta-5,7-diene 1 H-NMR(CDCl 3 )δ : 0.63(3H,s), 0.96(3H,d,J=6.3Hz), 1.06(3H,s), 1.22(6H,s), 3.41-4.00(7H,m), 5.33-5.40(1H,m), 5.68-5.73(1H,m) MS(m/z) : 504(M + ), 55(100%) UV λmax(nm) : 293, 281, 270 IR(cm -1 ) : 3420, 2950, 2900, 1480, 1390, 770 Example 7 2β-Butoxy-1α,3β,25-trihydroxycholesta-5,7-diene 1 H-NMR(CDCl 3 )δ : 0.63(3H,s), 0.93(3H,t,J=7.3Hz), 0.96(3H,d,J=6.3Hz), 1.07(3H,s), 1.21(6H,s), 3.40-3.52(1H,m), 3.66-3.77(2H,m), 3.84-4.00(2H,m), 5.33-5.32-5.40(1H,m), 5.67-5.74(1H,m) MS(m/z) : 488(M + ), 59(100%) UV λmax(nm) : 292, 281, 271 IR(cm -1 ) : 3450, 2950, 2900, 1490, 1390, 1100 Example 8 2β-(5-Hydroxypentoxy)-1α,3β,25-trihydroxycholesta-5,7-diene 1 H-NMR(CDCl 3 )δ : 0.63(3H,s), 0.96(3H,d,J=6.3Hz), 1.06(3H,s), 1.22(6H,s), 3.41-4.00(7H,m), 5.33-5.40(1H,m), 5.68-5.73(1H,m) MS(m/z) : 518(M + ), 59(100%) UV λmax(nm) : 293, 281, 270 IR(cm -1 ) : 3400, 2950, 2880, 1380, 1140, 970, 760 Examples 9 to 14 The following vitamin D 3 derivatives were synthesized from the products of Examples 3 to 8 by thermal isomerization after irradiation of U.V. light under the conventional conditions. Example 9 2β-butoxy-1α,3β-dihydroxy-9,10-secocholesta-5,7,10(19)-triene 1 H-NMR(CDCl 3 )δ: 0.55(3H,s), 0.86(6H,d,J=6.6Hz), 0.92(3H,d,J=6.0Hz), 0.94(3H,t,J=7.4Hz), 3.22(1H,dd,J=9.1,2.8Hz), 3.47-3.58(1H,m), 3.65-3.77(1H,m), 4.23(1H,brs), 4.29(1H,d,J=6.6Hz), 5.08(1H,s), 5.49(1H,s), 6.06(1H,d,J=11.2Hz), 6.36(1H,d,J=11.2Hz) MS(m/z) : 472(M + ), 109(100%) UV λmax(nm) : 264, λmin(nm) : 228 IR(cm -1 ) : 3400, 2950, 2860, 1460, 1380, 1100 Example 10 2β-cyclohexyloxy-1α,3β-dihydroxy-9,10-secocholesta-5,7,10(19)-triene 1 H-NMR(CDCl 3 )δ : 0.55(3H,s), 0.86(6H,d,J=6.6Hz), 0.92(3H,d,J=6.3Hz), 3.35(1H,dd,J=9.4,2.5Hz), 3.39-3.50(1H,m), 4.12-4.18(1H,m), 4.19-4.30(1H,m), 5.07(1H,s), 5.49(1H,s), 6.06(1H,d,J=11.4Hz), 6.36(1H,d,J=11.4Hz) MS(m/z) : 498(M + ), 56(100%) UV λmax(nm) : 264, λmin(nm) : 229 Example 11 2β-cyclohexyloxy-1α,3β,25-trihydroxy-9,10-secocholesta-5,7,10(19)-triene 1 H-NMR(CDCl 3 )δ : 0.55(3H,s), 0.94(3H,d,J=6.3Hz), 1.21(6H,s), 3.32-3.39(1H,m), 3.40-3.45(1H,m), 4.11-4.17(1H,m), 4.22-4.29(1H,m), 5.07(1H,s), 5.49(1H,s), 6.06(1H,d,J=11.3Hz), 6.34(lH,d,J=11.3Hz) MS(m/z) : 514(M + ), 55(100%) UV λmax(nm) : 264, λmin(nm) : 228 Example 12 2β-(4-hydroxybutoxy)-1α,3β,25-trihydroxy-9,10-secocholesta-5,7,10(19)-triene 1 H-NMR(CDCl 3 )δ: 0.55(3H,s), 0.59(3H,d,J=5.9Hz), 1.21(6H,s), 3.15-3.20(1H,m), 3.45-4.38(6H,m), 5.08(1H,s), 5.48(1H,s), 6.05(1H,d,J=11.6Hz), 6.36(1H,d,J=11.6Hz) MS(m/z) : 504(M + ), 59(100%) UV λmax(nm) : 263, λmin(nm) : 229 Example 13 2β-butoxy-1α,3β,25-trihydroxy-9,10-secocholesta-5,7,10(19)-triene 1 H-NMR (CDCl 3 )δ : 0.55(3H,s), 0.91-0.99(6H,m), 1.22(6H,s), 3.18-3.26(1H,m), 3.47-3.77(2H,m), 4.23(1H,brs), 4.29(1H,d,J=6.6Hz), 5.08(1H,s), 5.50(1H,s), 6.08(1H,d,J=12.2Hz), 6.34(1H,d,J=12.2Hz) MS(m/z) : 488(M + ), 59(100%) UV λmax(nm) : 264, λmin(nm) : 228 Example 14 2β-(5-hydroxypentoxy)-1α,3β,25-trihydroxy-9,10-secocholesta-5,7,10(19)-triene 1 H-NMR(CDCl 3 )δ: 0.55(3H,s), 0.94(3H,d,J=6.6Hz), 1.22(6H,s), 3.17-3.27(1H,m), 3.45-4.40(6H,m), 5.08(1H,s), 5.50(1H,s) MS(m/z) : 518(M + ), 69(100%) UV λmax(nm) : 264, λmin(nm) : 228 IR(cm -1 ) : 3400(br), 2930, 2860, 1460, 1380, 1100, 980, 740

Claims: A process for producing a compound represented by the formula (II): (wherein R 1 represents a hydrogen atom or a protective group, R 2 represents a hydrogen atom or a hydroxyl group, R 3 , R 4 , R 5 and R 6 represent that each of R 3 and R 4 , and R 5 and R 6 forms a double bond, or R 4 and R 5 form a double bond, and R 3 and R 6 bond to dienophile which is capable of protecting a conjugated double bond, and R 7 represents an alkyl group having from 1 to 6 carbon atoms, a cycloalkyl group or a hydroxyalkyl group having from 1 to 7 carbon atoms wherein the hydroxyl group may be protected), which comprises reacting an epoxy compound represented by the formula (I): (wherein R 1 represents a hydrogen atom or a protective group, R 2 represents a hydrogen atom or a hydroxyl group, R 3 , R 4 , R 5 and R 6 represent that each of R 3 and R 4 , and R 5 and R 6 forms a double bond, or R 4 and R 5 form a double bond, and R 3 and R 6 bond to dienophile which is capable of protecting a conjugated double bond), with an alcohol, wherein the reaction is carried out under a basic condition.

Inventors: KUBODERA NOBORU, KUBODERA, NOBORU, KUBODERA, NOBORU, CHUGAI SEIYAKU KABUSHIKI KAISHA
Applicants: CHUGAI PHARMACEUTICAL CO LTD, CHUGAI SEIYAKU KABUSHIKI KAISHA
Application year: 1993
Main classification: C07C401
IPC codes: C07J71, C07J9, C07C401